DiaVacs Announces a Strategic Collaboration with Profil Institute to Conduct Phase IB/IIA Randomized Clinical Trial of New Cell-Based Therapy for Type 1 Diabetes
Clinical program focused on reversing type 1 diabetes symptoms in patients diagnosed within six months of trial initiation
DiaVacs, Inc., a clinical stage biotechnology company focused on developing cell-based therapy for treatment of type 1 diabetes, and Profil® Institute for Clinical Research, Inc., an early phase clinical research organization focused on diabetes and obesity, announced today a strategic collaboration to conduct DiaVacs' phase Ib/IIa clinical trial. This clinical trial will study the safety and preliminary efficacy of DiaVacs' novel dendritic cell therapy for treatment of type 1 diabetes in patients who are newly diagnosed.
DiaVacs' proprietary technology is based on dendritic cell therapy. DiaVacs has perfected the immunology and technology to take a patient's own dendritic cells from their blood, modify them through the use of small interfering oligonucleotides, and then vaccinate the patient by simple injection of these modified cells under the skin using a small needle. The cells are taken up and trafficked to the pancreatic lymph nodes where they take up residence and induce tolerance. This cell-based therapy has been shown to be safe in phase I human trials and effective at halting disease progression in preclinical models of disease.
The double-blind, placebo-controlled study will begin by first enrolling 10 subjects who are at least 18 years of age with newly diagnosed type 1 diabetes (< 6 months from diagnosis). A fifteen month commitment will be required of all study participants, including multiple visits to Profil Institute's San Diego clinical facility. Thereafter, the study will expand the inclusion criteria to include younger participants who are newly diagnosed. The primary efficacy endpoint of the study is evidence of the return of insulin secretion by the pancreas. Additionally, various immune markers will be assessed for evidence that the autoimmune process responsible for type 1 diabetes has been altered.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
